Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ADA-011 |
| Synonyms | |
| Therapy Description |
ADA-011 is a monoclonal antibody targeting leukocyte immunoglobulin-like receptors B (LILRB), which potentially induces antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADA-011 | ADA 011|ADA011 | Immune Checkpoint Inhibitor 150 LILRB2 Antibody 12 | ADA-011 is a monoclonal antibody targeting leukocyte immunoglobulin-like receptors B (LILRB), which potentially induces antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05601219 | Phase I | ADA-011 | A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors | Terminated | USA | 0 |